Genmab — November 2019
-
-
De skriver sådan set i introduktionen til Candor abs, hvorfor det er vigtigt: The use of lenalidomide (LEN) and bortezomib (BTZ) in newly diagnosed multiple myeloma (MM) patients (pts), along with continuous or maintenance therapy paradigm have improved survival outcomes. However, many pts progress while on these agents or discontinue them due to toxicity. There is a need for novel, efficacious, and tolerable regimens that can treat MM pts who are exposed or refractory to LEN or BTZ.
-
God morgen.
-
Endelig ikke nogen nyheder i arbejdstiden. Det har jeg ikke tid til i dag.
-
Jeg har ansættelsessamtaler i dag. Satser på at arbejde halvtids i 2020. Det vil sige kun 60-70 timer ugenligt med fri om lørdagen. Det vil så betyde to nyansættelser i familiens firmaer.
-
Daratumumab is effective in the relapsed or refractory systemic light‐chain amyloidosis but associated with high infection burden in a frail real‐life population https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16282 http://sci-hub.tw/https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16282
-
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind